Macrogenics
Clinical trials sponsored by Macrogenics, explained in plain language.
-
New drug combo shows promise in slowing tough prostate cancer
Disease control CompletedThis study tested whether adding the experimental drug lorigerlimab to standard chemotherapy (docetaxel) can delay cancer growth in people with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. About 154 participants were rand…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 08, 2026 13:03 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a combination of two experimental drugs (vobramitamab duocarmazine and lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 05, 2026 12:08 UTC